Yes, @SnoopDogg torchbearer in #Gallarate 🔥🔥 #MilanoCortina2026 #Olympics #TorchRelay2026

When athletes devote large amounts of energy to running or cycling, they unconsciously cut back on energy output elsewhere go.nature.com/47fZPbt

#InterferonPower! Thrilled for our latest work @CellCellPress! With @dfrboehmer, we dug into tons of papers & created what we hope will be a go-to resource for immunologists & non-immunologist about type I, II, III (& IV😉) #interferons! Free link 👉 authors.elsevier.com/a/1leKG…

🧵1/ 🚨 Just out in Science Translational Medicine @ScienceTM our latest work @NaldiniLab: We show how tumor-targeted cytokines can rescue CAR-T function and recruit endogenous T cells to fight glioblastoma, the toughest brain cancer. 🔗science.org/doi/10.1126/scit… 👇 Here's a thread:

The wait is over, it’s back! 🧪 Granulocyte Meeting 2025 | 15–18 Sept | Shanghai. Big science. Big names. Big City. Don’t miss it. 🔗 g-meeting.org #Gmeeting2025 #Granulocytes #ThePowerOfMany

1/ 🚨 Hot off the press in @NatImmunol: CD4⁺ T cells can license Kupffer cells to rescue dysfunctional CD8⁺ T cells in the liver. Hepatitis B virus (HBV) infection is just the proving ground—this is a paradigm shift in tissue immunity. nature.com/articles/s41590-0… 🧵(1/11) 2/ Chronic HBV infection was the perfect stress test: intrahepatic CD8⁺ T cells are primed yet quickly stall. How to reignite them has been a major interest of our lab. (2/11) 3/ Pre‑activated helper CD4⁺ T cells solve the puzzle. They skip lymph nodes and head straight to the liver, where they form intimate triads with Kupffer cells (KCs), the resident macrophages patrolling sinusoids. (3/11) 4/ Through CD40L‑CD40 contact, those helpers re‑program KCs—turning tolerant scavengers into potent APC‑like cytokine factories. It’s on‑site immune engineering, not remote coaching. (4/11) 5/ Licensed KCs release a two‑part cocktail: • IL‑12 expands the helper pool • IL‑27 wakes up dysfunctional CD8⁺ T cells, restoring effector molecules and metabolic vigor. (5/11) 6/ Dendritic cells? Dispensable. Secondary lymphoid organs? Surgically removed or pharmacologically blocked—help still flows. Immunity can be fabricated in situright inside the parenchyma. (6/11) 7/ Remove KCs and the circuit collapses; block CD40L or IL‑27 and CD8⁺ T cells relapse into lethargy. The essential loop is: CD4 T cell ➜ KC ➜ IL‑27 ➜CD8 T cell. (7/11) 8/ IL‑27 isn’t just necessary—it’s sufficient. Recombinant IL‑27 revived antiviral CD8⁺ activity in mice and super‑charged HBV‑specific T cells from patients. (8/11) 9/ Why care beyond HBV? Tapping a CD4–IL‑27 axis could be a universal key to re‑arming liver‑resident CD8⁺ T cells against infections and cancer (9/11) 10/ The work reframes “CD4 help”: not a lymph‑node pep talk but an on‑site renovation that overrides local tolerance. Therapeutics that mimic KC licensing could deliver potency where it’s needed and spare the rest of the body. (10/11) 11/ Kudos to Valentina Venzin, Cristian Beccaria, all members of the @IannaconeLab & collaborators for charting this intrahepatic circuit. Expect Kupffer‑cell licensing and IL‑27 to enter conversations on cancer immunotherapy, vaccines and beyond. Thoughts welcome! 🙌 @ImmunoPodcast @profvrr @ERC_Research @EMBO @EMBO_YIP @ArmeniseHarvard @AIRC_it @MyUniSR @SanRaffaeleMI (11/11)